Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis.
Majed KhraishiBrad MillsonJohn WoolcottHeather JonesLisa MarshallNicolino RupertoPublished in: Pediatric rheumatology online journal (2019)
This study of Canadian claims-level data is the first large prespecified analysis of co-medication utilization following the initiation of ETN therapy in pediatric patients. A decline in both MTX and PRD use and dosage was observed and may be associated with benefits related to safety, tolerability, and overall healthcare costs.
Keyphrases
- juvenile idiopathic arthritis
- healthcare
- health insurance
- electronic health record
- big data
- disease activity
- rheumatoid arthritis
- high dose
- open label
- rheumatoid arthritis patients
- emergency department
- adverse drug
- randomized controlled trial
- ankylosing spondylitis
- clinical trial
- data analysis
- health information
- low dose